RxDoctor Payments Data

William Rolston, MD

Cardiovascular Disease · Metairie, LANPI 1619952017

Payments from drug & device makers

$577in general payments, 2019–2025

Across 39 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$149
  • Abbott$57
  • E.r. Squibb & Sons, L.L.C.$55
  • AstraZeneca$50
  • Bardy Diagnostics, Inc.$46
  • Johnson & Johnson$46
  • plus $174 from 8 others

What the payments were for

  • Food & beverage$56398%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$577 in reported general payments places this provider in the 20th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$86,341
Medicare patients
215
Services billed
1,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban294$290,393
XareltoRivaroxaban247$244,977
EntrestoSacubitril/Valsartan74$90,258
Repatha SureclickEvolocumab87$71,698
MultaqDronedarone Hcl17$26,934
FarxigaDapagliflozin Propanediol24$23,051
Repatha SyringeEvolocumab11$7,153
Dabigatran EtexilateDabigatran Etexilate Mesylate13$5,611
Metoprolol Succinate349$4,942
Nebivolol Hcl48$3,044
Pravastatin Sodium181$2,871
Ranolazine ErRanolazine27$2,824
Losartan Potassium214$2,559
Rosuvastatin Calcium174$2,400
Irbesartan101$2,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$290,393294 claims
Johnson & JohnsonXarelto$46$244,977247 claims
NovartisEntresto$149$90,25874 claims
Sanofi-aventis U.S. LLCMultaq$22$26,93417 claims
AstraZenecaFarxiga$50$23,05124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →